search

Active clinical trials for "Immune System Diseases"

Results 181-190 of 37852

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell...

Diffuse Large B Cell Lymphoma

This is an open-label, multicentre, randomised phase II trial in relapsed or refractory diffuse large B-cell lymphoma.

Recruiting47 enrollment criteria

Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis

Multiple Sclerosis

the aim of the study is to evaluate the effectiveness of partial-body cryotherapy (PBC) on the symptoms of patients with multiple sclerosis during a rehabilitation stay.

Recruiting11 enrollment criteria

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination...

LymphomaNon-Hodgkin

This is a first-in human, open-label, Phase 1 dose-escalation study in order to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for intravenous (IV) and/or subcutaneous (SC) dosing schemes of this combination treatment, and to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of this combination treatment in participants with relapsed/refractory B-cell non Hodgkin lymphoma (r/r NHL).

Recruiting35 enrollment criteria

Genotype-guided Treatment in DLBCL

Diffuse Large B Cell Lymphoma

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma

Recruiting25 enrollment criteria

Safety and Tolerability of FMT Capsules in Healthy Volunteers

Acute-graft-versus-host Disease

This is a two-part, randomized, double-blind, placebo-controlled, single center study to investigate the safety and tolerability of XBI-302 administered orally in healthy volunteers. The hypothesis of this study is that XBI-302 is safe and well tolerated with the proposed dosing regimens.

Recruiting23 enrollment criteria

Metformin Treatment in Progressive Multiple Sclerosis

Secondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Recruiting21 enrollment criteria

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's...

Sjogren Syndrome

A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)

Recruiting49 enrollment criteria

Chidamide Bridging for CAR-T Therapy

Non Hodgkin's Lymphoma

The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of CAR-T cells. This study will enroll approximately 120 subjects with recurrent or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Those with high expression of NOXA will receive conventional CAR-T treatment (without chidamide bridging), and those with low expression of NOXA will be randomly assigned 1:1 to those without or containing chidamide bridging. The purpose of this study was to evaluate the clinical response and safety of chidamide bridging.

Recruiting31 enrollment criteria

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

This is a Phase 1, multicenter, open-label study o evaluate the safety and efficacy of CART-BCMA in subjects with relapsed/refractory multiple myeloma.

Recruiting32 enrollment criteria

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder

This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.

Recruiting10 enrollment criteria
1...181920...3786

Need Help? Contact our team!


We'll reach out to this number within 24 hrs